Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
Exelixis, Inc. (Exelixis, we, our or us) is an oncology company innovating next-generation medicines and regimens at the forefront of cancer care. We have produced four marketed pharmaceutical products, two of which are formulations of our flagship molecule, cabozantinib, and we are steadily advancing and evolving our product pipeline portfolio, including our lead clinical asset, zanzalintinib, currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of certain forms of colorectal cancer (CRC), as well as the focus of an extensive late-stage clinical development program in other indications. With a rational and disciplined approach to investment, we are leveraging our internal experience and expertise and the strength of strategic partnerships, to identify and pursue opportunities across the landscape of scientific modalities, including small molecules and biotherapeutics, such as antibody-drug conjugates (ADCs). Sales related to cabozantinib account for the majority of our revenues.
Read the full filing description · filed 10 Feb 2026
At a glance
- Sector
- Healthcare
- Industry
- Biological Products, (No Diagnostic Substances)
- Employees (2026)
- 1,077
- Incorporated in
- DE
Sector is derived from the SEC industry classification.
1851 HARBOR BAY PARKWAY, ALAMEDA, CA, United States · 6508377000 · exelixis.com
Source: SEC filings. Information and analytics, not investment advice.